Use of Eylea for the Treatment of an Optic Nerve Hemangioma
| Status: | No longer available |
|---|---|
| Conditions: | Ocular, Hematology |
| Therapuetic Areas: | Hematology, Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/9/2017 |
This is a single patient investigative treatment study. The patient was diagnosed with a
retinal tumor in one eye. In the last 2 years, the patient has been treated with all
available and conventional therapies, including intraocular injections of Avastin and
Lucentis, steroids, and photodynamic therapy. Any positive results were short-term, and
caused an eventual decline in central vision. Aflibercept has been shown to be effective
against the growth of new vessels, secondary to macular degeneration. This study proposes
that it may also be more effective in treating this particular patient and case. The study
treatment plan is for 6 months initially, with the intention to continue treatment.
retinal tumor in one eye. In the last 2 years, the patient has been treated with all
available and conventional therapies, including intraocular injections of Avastin and
Lucentis, steroids, and photodynamic therapy. Any positive results were short-term, and
caused an eventual decline in central vision. Aflibercept has been shown to be effective
against the growth of new vessels, secondary to macular degeneration. This study proposes
that it may also be more effective in treating this particular patient and case. The study
treatment plan is for 6 months initially, with the intention to continue treatment.
The treatment plan will be to administer aflibercept 2.0 mg intravitreally every two to four
weeks for at least six consecutive injections. Prior to initiation of therapy and at each
study visit, a full ophthalmic examination, best-corrected visual acuity, and a complete
review of systems to monitor for any toxicity will be performed. In addition, the
investigators will perform fluorescein and indocyanine green angiography at baseline and
obtain color fundus photographs as well as spectral domain OCT images to properly document
the extent and degree of activity of the vascular tumor at baseline and at all study visits.
weeks for at least six consecutive injections. Prior to initiation of therapy and at each
study visit, a full ophthalmic examination, best-corrected visual acuity, and a complete
review of systems to monitor for any toxicity will be performed. In addition, the
investigators will perform fluorescein and indocyanine green angiography at baseline and
obtain color fundus photographs as well as spectral domain OCT images to properly document
the extent and degree of activity of the vascular tumor at baseline and at all study visits.
Inclusion Criteria:
- retinal hemangioma
- previously treated with conventional therapies, including Avastin, Lucentis, steroid,
and photodynamic therapy, with less than ideal results
Exclusion Criteria:
- ongoing reevaluation of adverse events, including inflammation, elevated intraocular
pressure, or any suspected toxicity from aflibercept
We found this trial at
1
site
New York, New York 10022
Principal Investigator: Jason S Slakter, MD
Phone: 212-452-6965
Click here to add this to my saved trials
